General Biologicals Corporation
General Biologicals Corporation engages in the research, development, manufacture, and sales of in-vitro diagnostics in Taiwan and internationally. It offers ELISA and chemiluminescence immunoassay, molecular and cell diagnostic, and point of care testing services. The company also provides COVID-19, digital pathology, and contract development manufacturing organization solutions; blood screening… Read more
Market Cap & Net Worth: General Biologicals Corporation (4117)
General Biologicals Corporation (TWO:4117) has a market capitalization of $9.20 Million (NT$304.54 Million) as of March 18, 2026. Listed on the TWO stock exchange, this Taiwan-based company holds position #31593 globally and #1866 in its home market, demonstrating a -62.45% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying General Biologicals Corporation's stock price NT$4.30 by its total outstanding shares 70824370 (70.82 Million).
General Biologicals Corporation Market Cap History: 2026 to 2026
General Biologicals Corporation's market capitalization history from 2026 to 2026. Data shows growth from $9.20 Million to $9.20 Million (0.00% CAGR).
General Biologicals Corporation Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how General Biologicals Corporation's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 4117 by Market Capitalization
Companies near General Biologicals Corporation in the global market cap rankings as of March 18, 2026.
Key companies related to General Biologicals Corporation by market ranking:
- Zoetis Inc (NYSE:ZTS): Ranked #410 globally with a market cap of $53.52 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #434 globally with a market cap of $49.87 Billion USD.
- Takeda Pharmaceutical Co. Ltd. (PINK:TKPHF): Ranked #457 globally with a market cap of $47.47 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #721 globally with a market cap of $28.19 Billion USD ( CN¥206.84 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #410 | Zoetis Inc | NYSE:ZTS | $53.52 Billion | $121.68 |
| #434 | Haleon plc | NYSE:HLN | $49.87 Billion | $10.60 |
| #457 | Takeda Pharmaceutical Co. Ltd. | PINK:TKPHF | $47.47 Billion | $30.07 |
| #721 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $28.19 Billion | CN¥55.11 |
General Biologicals Corporation Historical Marketcap From 2026 to 2026
Between 2026 and today, General Biologicals Corporation's market cap moved from $9.20 Million to $ 9.20 Million, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | NT$9.20 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of General Biologicals Corporation was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $9.20 Million USD |
| MoneyControl | $9.20 Million USD |
| MarketWatch | $9.20 Million USD |
| marketcap.company | $9.20 Million USD |
| Reuters | $9.20 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.